Body-composition changes in patients who gain weight while receiving megestrol acetate.

PURPOSE Randomized placebo-controlled clinical trials have now established that megestrol acetate causes appetite stimulation and weight gain in patients with anorexia and/or cachexia. There is a paucity of available data to delineate the substance of this increased weight. PATIENTS AND METHODS Using dual-energy x-ray absorptiometry and tritiated body water methodologies, we performed body-composition measurements in 12 patients with advanced cancer before the institution of oral megestrol acetate (800 mg/d) and at subsequent 2-month intervals. RESULTS Seven of the 12 patients gained weight (2.1 to 16.5 kg) and had repeat body-composition measurements performed at the time of maximum weight gain. The vast majority of the gained weight was clearly from an increase in adipose tissue, while there was a suggestion that an increase in body fluid was responsible for a minority of the weight gain. CONCLUSION Megestrol acetate-induced weight gain is primarily the result of an increase in body mass.

[1]  J. Aisner,et al.  Megestrol acetate in cancer anorexia and weight loss , 2010, Cancer.

[2]  J. Feliu,et al.  Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? , 1991, Journal of the National Cancer Institute.

[3]  C. Spurr,et al.  High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Bruera,et al.  A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer , 1990, Cancer.

[5]  D. Schaid,et al.  Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. , 1990, Journal of the National Cancer Institute.

[6]  R B Mazess,et al.  Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. , 1990, The American journal of clinical nutrition.

[7]  S. Heymsfield,et al.  Body fat from body density: underwater weighing vs. dual-photon absorptiometry. , 1989, The American journal of physiology.

[8]  D. Schaid,et al.  A Prospective, Randomized Controlled Trial of Megestrol Acetate Among High‐Risk Patients with Resected Malignant Melanoma , 1989, American journal of clinical oncology.

[9]  J. V. Von Roenn,et al.  Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. , 1988, Annals of internal medicine.

[10]  M. Jensen,et al.  Measurement of body potassium with a whole-body counter: relationship between lean body mass and resting energy expenditure. , 1988, Mayo Clinic proceedings.

[11]  H C Lukaski,et al.  Methods for the assessment of human body composition: traditional and new. , 1987, The American journal of clinical nutrition.

[12]  J. Hainsworth,et al.  High-dose pilot studies in extensive-stage small-cell lung cancer. , 1986, Seminars in oncology.

[13]  J. Wolter,et al.  Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. , 1985, Seminars in oncology.

[14]  Lawrence A Leiter,et al.  Survival during fasting may depend on fat as well as protein stores. , 1982, JAMA.

[15]  G. Lesser,et al.  Body water compartments with human aging using fat-free mass as the reference standard. , 1979, The American journal of physiology.